SlideShare une entreprise Scribd logo
1  sur  93
Cancer stem cells:  implications in the  clinical setting  Malcolm Alison; m.alison@qmul.ac.uk 4 th  April 2011
 
 
 
Time Initiator Promoter Initiators  &   promoters * Tumours Tumours No tumours DMBA TPA
 
SVZ astrocytic ribbon
 
Cancer Stem Cells The idea is not new
Hamburger and Salmon 1977, Science The plating efficiency of most 1 0  tumours is <1% PE =  macroscopic colonies formed number of tumour cells plated
The tumour battleground
Markers Cancer stem cells
 
 
Flow Cytometry
Fluorescence Activation Process  (or Immunofluorescence) FITC FITC Antibodies recognize specific molecules in the surface of some cells But not others When the cells are analyzed by flow cytometry the cells expressing the marker for which the antibody is specific will manifest fluorescence. Cells who lack the marker will not manifest fluorescence Antibodies are artificially conjugated to fluorochromes Antibodies FITC FITC FITC FITC
Fluorescence intensity 10 1 10 4 10 3 10 2 Relative fluorescence intensity Number of Events FITC FITC FITC FITC FITC FITC FITC FITC FITC FITC
Y X Z Y Z X Cells are presented to the laser using principles of hydrodynamic focusing  Laser optics Laser Beam Flow chamber Sheath Sample
2 Parameter Histogram FITC FL PE FL Negative Population Single Positive FITC Population Single Positive PI Population Double Positive Population
 
Xenografting
 
 
 
 
The pre-eminence of ALDH as  a cancer stem cell marker  Responsible for the oxidation (detoxification) of  cytotoxic aldehydes to carboxylic acids RCHO + NAD +  + H 2 0  RCOOH + NADH + H + : a major cellular defence mechanism
 
Vitamin A Differentiation
 
 
Charafe-Jauffret et al.
Only 21 of 203 cases were ALDH1 +
 
 
Victoria L Bautch
How do you increase CSC numbers
 
p53 MDM2 =
The cancer stem cells bandwagon
Malignant melanoma
 
 
 
In Ptc +/-  mice, Math1 + /CD15 +  (SSEA1) selects for TPCs
E-Cadherin
 
 
 
Options for therapy •  Irradiation •  Self-renewal pathways (Wnts, Notch, Hedgehog, PTEN-Akt) •  Aldehyde dehydrogenase activity •  EMT •  ABC transporters •  miRNAS and HDACi •  Targeting the niche
Cancer stem cells are very  chemoresistant and radioresistant
Front line treatment of pancreatic cancer enriches for CSCs In vitro In vivo
Colorectal xenograft treated with cyclophosphamide but  Dylla et al.
 
 
Time Selection pressures: nutrition/oxygen/immunity/therapy Clonal co-existence Clone 1 Clone 3 Clone 2
 
A more complex subclonal architecture in ALL Does genetic diversity affect the nature of tumour propagating cells? Yes, the potency, but  not  the phenotype (CD34 + CD38 -/low CD19 + )
 
Enrich Less apoptosis Enhanced DDR
Targeting L1CAM with shRNA sensitises GSCs to irradiation
 
Induce differentiation = reduced sphere formation Inhibit ALDH = increased  sphere formation
Dissociated CK20 colonosphere  cells treated  in vitro  for 6 days
 
 
 
 
 
Hedgehog signalling
Keeping things stem-like Mdm2
 
Hedgehog inhibitor: Cyclopamine Corn Lilly Cyclopia Poor oral bioavailability; short half-life
 
 
 
Reduces Gli expression Reduces ALDH bri  % * Blocked metastasis
 
 
 
GFs  PI3K  PIP3  Akt PTEN  ABCG2
Knock-down of PTEN increases efficiency of mammosphere formation
Combination therapy works
 
 
 
 
Sulforaphane
 
Related to a large reduction in ALDEFLUOR+ cells
also inhibits xenograft growth
•  Cancer is a stem cell disease •  Tumours have stem cells: ‘cancer stem cells’ •  Therapy should target cancer stem cells
 
 

Contenu connexe

Tendances

Cancer stem cell dr.neelam ahirwar
Cancer stem cell dr.neelam ahirwarCancer stem cell dr.neelam ahirwar
Cancer stem cell dr.neelam ahirwarDr.Neelam Ahirwar
 
CANCER STEM CELLS
CANCER STEM CELLSCANCER STEM CELLS
CANCER STEM CELLSsathish sak
 
Tumor stem cell reprogramming as a driver of cancer as
Tumor stem cell reprogramming as a driver of cancer asTumor stem cell reprogramming as a driver of cancer as
Tumor stem cell reprogramming as a driver of cancer asmds-web
 
Stem cells as a cause of cancers
Stem cells as a cause of cancersStem cells as a cause of cancers
Stem cells as a cause of cancersAndleeb Sultana
 
Cellular level cancer therapy
Cellular level  cancer therapyCellular level  cancer therapy
Cellular level cancer therapySuganyaPaulraj
 
Biology of cancer lecture 5 cell cycle Karobi Moitra
Biology of cancer lecture 5 cell cycle Karobi MoitraBiology of cancer lecture 5 cell cycle Karobi Moitra
Biology of cancer lecture 5 cell cycle Karobi MoitraKarobi Moitra CFD, MS, PhD
 
Hallmarks of Cancer - Sustained Proliferative Signaling
Hallmarks of Cancer  - Sustained Proliferative SignalingHallmarks of Cancer  - Sustained Proliferative Signaling
Hallmarks of Cancer - Sustained Proliferative SignalingLiam Arnade-Colwill
 
Hallmarks of Cancer - Classical vs Metabolic approach
Hallmarks of Cancer - Classical vs Metabolic approachHallmarks of Cancer - Classical vs Metabolic approach
Hallmarks of Cancer - Classical vs Metabolic approachSreepadmanabh M
 
Cancer therapy at gene level
Cancer therapy at gene levelCancer therapy at gene level
Cancer therapy at gene levelSuganyaPaulraj
 
Leukemic stem cells
Leukemic stem cellsLeukemic stem cells
Leukemic stem cellsmds-web
 
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1
Transplant in pediatrics in Acute lymphoblastic  Luekemia in CR1Transplant in pediatrics in Acute lymphoblastic  Luekemia in CR1
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1Dr. Liza Bulsara
 

Tendances (20)

Cancer stem cell dr.neelam ahirwar
Cancer stem cell dr.neelam ahirwarCancer stem cell dr.neelam ahirwar
Cancer stem cell dr.neelam ahirwar
 
CANCER STEM CELLS
CANCER STEM CELLSCANCER STEM CELLS
CANCER STEM CELLS
 
CANCER STEM CELLS
CANCER STEM CELLSCANCER STEM CELLS
CANCER STEM CELLS
 
Tumor stem cell reprogramming as a driver of cancer as
Tumor stem cell reprogramming as a driver of cancer asTumor stem cell reprogramming as a driver of cancer as
Tumor stem cell reprogramming as a driver of cancer as
 
cancer
cancercancer
cancer
 
Stem cells as a cause of cancers
Stem cells as a cause of cancersStem cells as a cause of cancers
Stem cells as a cause of cancers
 
Hallmarks in cancer
Hallmarks in cancerHallmarks in cancer
Hallmarks in cancer
 
Cellular level cancer therapy
Cellular level  cancer therapyCellular level  cancer therapy
Cellular level cancer therapy
 
Biology of cancer lecture 5 cell cycle Karobi Moitra
Biology of cancer lecture 5 cell cycle Karobi MoitraBiology of cancer lecture 5 cell cycle Karobi Moitra
Biology of cancer lecture 5 cell cycle Karobi Moitra
 
Hallmarks of Cancer
Hallmarks of Cancer Hallmarks of Cancer
Hallmarks of Cancer
 
Hallmarks of Cancer - Sustained Proliferative Signaling
Hallmarks of Cancer  - Sustained Proliferative SignalingHallmarks of Cancer  - Sustained Proliferative Signaling
Hallmarks of Cancer - Sustained Proliferative Signaling
 
Hallmarks of Cancer - Classical vs Metabolic approach
Hallmarks of Cancer - Classical vs Metabolic approachHallmarks of Cancer - Classical vs Metabolic approach
Hallmarks of Cancer - Classical vs Metabolic approach
 
Dicer mutation in tumors
Dicer mutation in tumorsDicer mutation in tumors
Dicer mutation in tumors
 
Single cell pcr
Single cell pcrSingle cell pcr
Single cell pcr
 
Cancer therapy at gene level
Cancer therapy at gene levelCancer therapy at gene level
Cancer therapy at gene level
 
Leukemic stem cells
Leukemic stem cellsLeukemic stem cells
Leukemic stem cells
 
TriStar CSC
TriStar CSCTriStar CSC
TriStar CSC
 
Molecular basis of Cancer
Molecular basis of CancerMolecular basis of Cancer
Molecular basis of Cancer
 
Hallmarks of cancer
Hallmarks of cancerHallmarks of cancer
Hallmarks of cancer
 
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1
Transplant in pediatrics in Acute lymphoblastic  Luekemia in CR1Transplant in pediatrics in Acute lymphoblastic  Luekemia in CR1
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1
 

Similaire à MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting

Prof.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchProf.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchmohammed4450
 
Mariano Barbacid-El cáncer como consecuencia del envejecimiento
Mariano Barbacid-El cáncer como consecuencia del envejecimientoMariano Barbacid-El cáncer como consecuencia del envejecimiento
Mariano Barbacid-El cáncer como consecuencia del envejecimientoFundación Ramón Areces
 
IDO pathway from bench to clinic
IDO pathway from bench to clinicIDO pathway from bench to clinic
IDO pathway from bench to clinicHoussein A Sater
 
Cellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid LeukemiaCellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid Leukemiaspa718
 
Molecular basis of head and neck cancer
Molecular basis of head and neck cancerMolecular basis of head and neck cancer
Molecular basis of head and neck cancerSREENIVAS KAMATH
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Cytokinine
 
Poster_NSW Translational Breast Cancer Research Symposium 2016_Christina Konrad
Poster_NSW Translational Breast Cancer Research Symposium 2016_Christina KonradPoster_NSW Translational Breast Cancer Research Symposium 2016_Christina Konrad
Poster_NSW Translational Breast Cancer Research Symposium 2016_Christina KonradChristina Konrad
 
Cll pathogenesis and targeted therapy
Cll pathogenesis and targeted therapyCll pathogenesis and targeted therapy
Cll pathogenesis and targeted therapyabha singh
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)Vinblast
 
Receptor Tyrosine Kinases
Receptor Tyrosine KinasesReceptor Tyrosine Kinases
Receptor Tyrosine Kinasesfondas vakalis
 
Immunotherapy advances in lung cancer
Immunotherapy advances in lung cancerImmunotherapy advances in lung cancer
Immunotherapy advances in lung cancerAlok Gupta
 
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Mark Lipstein
 
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTSTREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTSspa718
 
Monoclonal antibodies [autosaved]
Monoclonal  antibodies [autosaved]Monoclonal  antibodies [autosaved]
Monoclonal antibodies [autosaved]Fariha Shikoh
 
Tumor immunology dr. ihsan alsaimary
Tumor immunology  dr. ihsan alsaimaryTumor immunology  dr. ihsan alsaimary
Tumor immunology dr. ihsan alsaimarydr.Ihsan alsaimary
 
Radiosenitizers and radioprotectors
Radiosenitizers and radioprotectorsRadiosenitizers and radioprotectors
Radiosenitizers and radioprotectorsDhiman Das
 

Similaire à MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting (20)

Prof.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchProf.dr.moh'd sorour bch
Prof.dr.moh'd sorour bch
 
Mariano Barbacid-El cáncer como consecuencia del envejecimiento
Mariano Barbacid-El cáncer como consecuencia del envejecimientoMariano Barbacid-El cáncer como consecuencia del envejecimiento
Mariano Barbacid-El cáncer como consecuencia del envejecimiento
 
IDO pathway from bench to clinic
IDO pathway from bench to clinicIDO pathway from bench to clinic
IDO pathway from bench to clinic
 
Cellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid LeukemiaCellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid Leukemia
 
Molecular basis of head and neck cancer
Molecular basis of head and neck cancerMolecular basis of head and neck cancer
Molecular basis of head and neck cancer
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)
 
Poster_NSW Translational Breast Cancer Research Symposium 2016_Christina Konrad
Poster_NSW Translational Breast Cancer Research Symposium 2016_Christina KonradPoster_NSW Translational Breast Cancer Research Symposium 2016_Christina Konrad
Poster_NSW Translational Breast Cancer Research Symposium 2016_Christina Konrad
 
Dr g vassiliou
Dr g vassiliouDr g vassiliou
Dr g vassiliou
 
Rt in lymphoma
Rt in lymphomaRt in lymphoma
Rt in lymphoma
 
Cll pathogenesis and targeted therapy
Cll pathogenesis and targeted therapyCll pathogenesis and targeted therapy
Cll pathogenesis and targeted therapy
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)
 
Receptor Tyrosine Kinases
Receptor Tyrosine KinasesReceptor Tyrosine Kinases
Receptor Tyrosine Kinases
 
Immunotherapy advances in lung cancer
Immunotherapy advances in lung cancerImmunotherapy advances in lung cancer
Immunotherapy advances in lung cancer
 
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
 
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTSTREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
 
New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...
New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...
New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...
 
Monoclonal antibodies [autosaved]
Monoclonal  antibodies [autosaved]Monoclonal  antibodies [autosaved]
Monoclonal antibodies [autosaved]
 
Tumor immunology dr. ihsan alsaimary
Tumor immunology  dr. ihsan alsaimaryTumor immunology  dr. ihsan alsaimary
Tumor immunology dr. ihsan alsaimary
 
Radiosenitizers and radioprotectors
Radiosenitizers and radioprotectorsRadiosenitizers and radioprotectors
Radiosenitizers and radioprotectors
 
Apoptosis
Apoptosis Apoptosis
Apoptosis
 

Plus de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Plus de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting

Notes de l'éditeur

  1. 6